Pamukkale University

pau.edu.tr

Total trials

303

Active

42

Phase 3

0

Total enrollment

25,737

Read this sponsor's pipeline like an analyst.

Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.

~15-30 sec · cached for 24h

Pipeline matrix

Showing 5 of 5 active programs · click any cell for trials

InterventionEarly Phase 1Phase 1Phase 2Phase 3Phase 4N/ATotal
Fluticasone propionate nasal spray1
Fluticasone propionate-azelastine nasal spray1
Autologous Platelet-Rich Plasma1
Conditioned serum1
intracochlear platelet rich fibrin administration1

Next readouts

  • 2023-10-30
  • 2025-12-01
  • 2026-06-30

Top conditions

  • Stroke10
  • Pain6
  • Multiple Sclerosis6
  • Urinary Bladder, Overactive6
  • Hand Injuries5
  • Cerebral Palsy5
  • Elderly4
  • Flexibility4

Frequently asked questions about Pamukkale University

How many clinical trials does Pamukkale University have on ClinicalTrials.gov?
Pamukkale University is listed as the lead sponsor on 303 clinical trials in ClinicalTrials.gov, 42 of which are currently active (recruiting, enrolling, or ongoing).
How many of Pamukkale University's trials are in Phase 3?
0 of Pamukkale University's trials are in Phase 3, spread across 5 active drug programs.
What therapeutic areas does Pamukkale University focus on?
Pamukkale University's most-studied conditions on ClinicalTrials.gov are Stroke, Pain, Multiple Sclerosis, Urinary Bladder, Overactive, Hand Injuries.
When are Pamukkale University's next clinical trial readouts?
Pamukkale University has 3 upcoming primary-completion readouts tracked here; the soonest is “INTRANASAL FLUTICASONE VERSUS FLUTICASONE-AZELASTINE COMBINATION”, expected around 2023-10-30.